Cytokinetics Sets New 12-Month Low at $3.84 (CYTK)
Cytokinetics (NASDAQ:CYTK)’s share price reached a new 52-week low on Thursday , American Banking and Market News reports. The stock traded as low as $3.84 and last traded at $3.88, with a volume of 376,292 shares changing hands. The stock had previously closed at $4.09.
Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Cytokinetics in a research note on Thursday, July 10th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $8.60.
The stock has a 50-day moving average of $4.29 and a 200-day moving average of $6.34. The company’s market cap is $141.3 million.
Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Wednesday, July 30th. The company reported ($0.23) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.32) by $0.09. The company had revenue of $7.80 million for the quarter, compared to the consensus estimate of $7.01 million. On average, analysts predict that Cytokinetics will post $-0.99 earnings per share for the current fiscal year.
Cytokinetics, Incorporated (NASDAQ:CYTK) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.